98%
921
2 minutes
20
Genomic alterations driving tumorigenesis in sinonasal malignancies remain largely unexplored. Here, we perform an loss-of-function screen using a pooled custom single-guide library delivered to the sinonasal cavity by adeno-associated virus vector to identify cancer driver genes across diverse sinonasal malignancies. This approach yielded sinonasal malignancies with diverse histologies, including sinonasal squamous cell carcinoma, adenocarcinoma, poorly differentiated sinonasal carcinoma, and sinonasal neuroendocrine tumors characteristic of olfactory neuroblastoma. Surprisingly, rather than observing distinct sgRNA profiles across sinonasal tumor subtypes, common recurrent mutations were identified in (79%), (74%), and (68%) across malignancies with distinct histologies. Utilizing an orthogonal approach, we confirmed that were required for sinonasal tumorigenesis. Given that loss-of-function in and may lead to increased Ras activity and downstream MEK signaling, we tested small molecule targeting of the RAS-MAPK pathway in sinonasal malignancies. Indeed, both tumor cell lines derived from our loss-of-function approach as well as from human sinonasal malignancies displayed significant sensitivity to MEK inhibition in standard culture and organoid models. These findings demonstrate that loss of NF1 and RASA1-mediated Ras-GAP activity leads to Ras activation and downstream MEK signaling which is a potential common target throughout major sinonasal tumor subtypes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139907 | PMC |
http://dx.doi.org/10.1101/2025.05.19.654661 | DOI Listing |
Cureus
August 2025
Department of Oncology, University of Warmia and Mazury in Olsztyn, Olsztyn, POL.
Management of recurrent adenoid cystic carcinoma (ACC) in elderly patients remains challenging due to comorbidities, functional impairments, and anatomically complex tumor locations that complicate surgical access and increase operative risk. The ZAP-X Gyroscopic Radiosurgery System (ZAP Surgical Systems, Inc., San Carlos, CA, USA) offers a highly precise, non-invasive treatment modality, potentially suitable for salvage therapy in previously irradiated fields and in medically inoperable patients.
View Article and Find Full Text PDFHead Neck
September 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Flap complications following maxillectomy, reconstruction, and adjuvant proton beam therapy (PBT) for primary maxillary and sinonasal malignancies are not well described.
Methods: This retrospective cohort study included consecutive patients treated between 2016 and 2023 from a single-institutional database.
Results: Thirteen patients were identified with a median follow-up of 26 months.
Am J Case Rep
September 2025
Department of Otolaryngology - Head and Neck Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
BACKGROUND Pediatric sinonasal tumors are rare, accounting for about 4% of all pediatric head and neck neoplasms. Due to their nonspecific symptoms such as nasal obstruction, epistaxis, and facial pain, these tumors often present diagnostic challenges and lead to delays in managment. Early and accurate diagnosis is crucial to optimize clinical outcomes.
View Article and Find Full Text PDFLab Invest
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA. Electronic address:
Sinonasal mucosal melanoma (SNMM) is a rare aggressive malignancy of the sinonasal tract. Due to its advanced clinical presentation and frequent late-stage diagnosis, the 5-year survival rate is less than 30%, with an even worse prognosis in patients with distant metastasis (SNMM-M). Therefore, characterizing the molecular landscape of SNMM may provide novel therapeutic targets for SNMM-M.
View Article and Find Full Text PDFInt Forum Allergy Rhinol
September 2025
Department of Otolaryngology, University of California Irvine, Irvine, California, USA.
The goal of this American Rhinologic Society expert practice statement (EPS) is to summarize the best available evidence for surveillance strategies following definitive treatment of sinonasal malignancy. Topics discussed include components of surveillance, including endoscopy and imaging subtypes, frequency and length of surveillance, and highlights of some specific pathologies that warrant special consideration. This EPS was developed following the recommended methodology and approval process as previously outlined.
View Article and Find Full Text PDF